NCT06682000

Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients With Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 192 (actual)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients with Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy

Conditions

• Hypertension
• Essential Hypertension

Interventions

Type	Name	Description
DRUG	DWC202404, DWC202314	\- 2 tablet, Oral, Once a day
DRUG	DWC202404, DWC202314P	\- 2 tablet, Oral, Once a day

Timeline

• Start date: 2025-01-01
• Primary completion: 2025-10-02
• Completion: 2025-10-02
• First posted: 2024-11-12
• Last updated: 2026-02-06

Locations

1 site across 1 country: South Korea